Correspondence 0001493152-23-044736 from CDT Equity Inc. (CDT)

CDT Equity Inc.
Date: Dec. 13, 2023 · CIK: 0001896212 · Accession: 0001493152-23-044736

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-275056

Date

Dec. 13, 2023

Author

CONDUIT

Form

CORRESP

Company

CDT Equity Inc.

Letter

VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Re: Conduit Pharmaceuticals Inc. (the “Company”) Registration Statement on Form S-1, as amended File No. 333-275056 (the “Registration Statement”)

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement be declared effective by the Securities and Exchange Commission at 4:30 p.m., Eastern Time on December 15, 2023, or as soon as practicable thereafter.

Please call Todd Mason at (212) 908-3946 of Thompson Hine LLP to confirm the effectiveness of the Registration Statement or with any questions.

[Signature Page Follows]

Sincerely,
CONDUIT
PHARMACEUTICALS INC.

Show Raw Text

CORRESP
1
filename1.htm

CONDUIT
PHARMACEUTICALS INC.

4995
Murphy Canyon Road, Suite 300

San
Diego, CA 92134

December
13, 2023

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

    Re:
    Conduit
    Pharmaceuticals Inc. (the “Company”)

    Registration
    Statement on Form S-1, as amended

    File
    No. 333-275056 (the “Registration Statement”)

Dear
Ladies and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the above-referenced Registration Statement
be declared effective by the Securities and Exchange Commission at 4:30 p.m., Eastern Time on December 15, 2023, or as soon as practicable
thereafter.

Please
call Todd Mason at (212) 908-3946 of Thompson Hine LLP to confirm the effectiveness of the Registration Statement or with any questions.

[Signature
Page Follows]

    Sincerely,

    CONDUIT
    PHARMACEUTICALS INC.

    By:

    /s/
    David Tapolczay

    Name:

    David
    Tapolczay

    Title:

    Chief
    Executive Officer

SecProbe.io